

INVESTOR OVERVIEW

A non-invasive sampling breakthrough for mass-market home diagnostics.

Our proprietary liquid concentrator replaces invasive swabs, turning painless liquid samples into lab-grade results to break the final barrier to widespread at-home testing.



Sample-agnostic. Modular. Endlessly applicable.

👤 Human health

🐾 Animal health

🍷 Food safety

THE CHALLENGE

Sample collection is the single biggest barrier in home diagnostics.

Accurate results demand **invasive collection**: a painful swab for STIs, a gag-inducing throat swab for strep. The FDA won't clear at-home tests built on methods this invasive, so the most-needed tests stay **locked in the clinic**.

THE HERO SOLUTION · HOW IT WORKS

One painless sample. Three simple steps to lab-grade results.

▶ Watch the product in action

**01 COLLECT****Painless Liquid Sampling**

Users provide a simple gargle or urine sample directly into the device. No swabs required.

**02 CONCENTRATE****Hand-powered, lab-grade**

Twisting the device shut forces the sample through an integrated filter, trapping the diagnostic target and rinsing the waste away. No labs, no machinery.

**03 TEST****Ready for any test**

The concentrated sample is released directly into any standard rapid or lab test, ready for a fast, accurate result.

APPLICATIONS & MARKET SIZE

One platform across high-volume, diverse global industries.

CURRENT FOCUS

Sexual Health (STIs) \$3.20B

\$5.90B projected market by 2033 (8.9% CAGR from 2026)

Strep A \$1.25B

No FDA-cleared at-home test exists today

NEAR-TERM PIPELINE *

Food Pathogen Testing \$6.6B

Tuberculosis \$2.70B

Bovine Mastitis \$2.3B

An \$11B+ adjacent market for the same platform.

2026 TAM estimates. Sources available in the investor section of our website.

GO TO MARKET

One platform, two parallel routes to market.

Strategic Partnerships & OEM

B2B

Licensing our platform to global leaders to upgrade existing tests and unlock at-home capabilities in adjacent markets (food safety, veterinary, TB), driving high-margin royalties with minimal overhead.

Partner outreach: November

Proprietary Consumer Diagnostics

CONSUMER

Building our own direct-to-consumer brand, starting with our swab-free **Strep A** test as the initial launch, capturing maximum commercial margins on our core health applications.

In development · Not yet FDA-cleared.

► Watch the strep test video

DEFENSIBILITY

A defensible patent moat around the core platform.

11

PATENT FAMILIES

9

U.S. PATENTS ISSUED

7

COUNTRIES PROTECTED

TEAM

Operators with an exit and deep regulatory credibility.



Robert Levitz
CHIEF EXECUTIVE OFFICER

Kellogg (Northwestern) MBA. Former CEO of **Green Smoke**, acquired by Altria for \$130M.



Lazar Fruchter, MD
CHIEF MEDICAL OFFICER

Pediatrician, board-certified in **allergy & clinical immunology**; fellowship at Boston Children's Hospital.



Susan Alpert, PhD, MD
SR. REGULATORY ADVISOR

Former Director of the **FDA's Office of Device Evaluation**; ex-VP Global Regulatory at **Medtronic**.

THE ROUND

\$3M raise

WHAT IT FUNDS: NEXT 12 MONTHS

- Production tooling & small-scale manufacturing
- Dual Strep A + STI clinical trials (from December)
- B2B partnerships & adjacent applications
- Appoint investment banking partner at Month 12 to accelerate global market expansion.